Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19
Daniel J. Schuster, Shelly Karuna, Caroline Brackett, Martina Wesley, Shuying S. Li, Nathan Eisel, DeAnna Tenney, Sir’Tauria Hilliard, Nicole L. Yates, Jack R. Heptinstall, LaTonya D. Williams, Xiaoying Shen, Robert Rolfe, Robinson Cabello, Lu Zhang, Sheetal Sawant, Jiani Hu, April Kaur Randhawa, Ollivier Hyrien, John A. Hural, Lawrence Corey, Ian Frank, Georgia D. Tomaras, Kelly E. Seaton, HVTN 405/HPTN 1901 Study Team
Daniel J. Schuster, Shelly Karuna, Caroline Brackett, Martina Wesley, Shuying S. Li, Nathan Eisel, DeAnna Tenney, Sir’Tauria Hilliard, Nicole L. Yates, Jack R. Heptinstall, LaTonya D. Williams, Xiaoying Shen, Robert Rolfe, Robinson Cabello, Lu Zhang, Sheetal Sawant, Jiani Hu, April Kaur Randhawa, Ollivier Hyrien, John A. Hural, Lawrence Corey, Ian Frank, Georgia D. Tomaras, Kelly E. Seaton, HVTN 405/HPTN 1901 Study Team
View: Text | PDF
Research Article AIDS/HIV COVID-19

Lower SARS-CoV-2–specific humoral immunity in people living with HIV-1 recovered from nonhospitalized COVID-19

Abstract

People living with HIV-1 (PLWH) exhibit more rapid antibody decline following routine immunization and elevated baseline chronic inflammation than people without HIV-1 (PWOH), indicating potential for diminished humoral immunity during SARS-CoV-2 infection. Conflicting reports have emerged on the ability of PLWH to maintain humoral protection against SARS-CoV-2 coinfection during convalescence. It is unknown whether peak COVID-19 severity, along with HIV-1 infection status, associates with the quality and quantity of humoral immunity following recovery. Using a cross-sectional observational cohort from the United States and Peru, adults were enrolled 1–10 weeks after SARS-CoV-2 infection diagnosis or symptom resolution. Serum antibodies were analyzed for SARS-CoV-2–specific response rates, binding magnitudes, ACE2 receptor blocking, and antibody-dependent cellular phagocytosis. Overall, (a) PLWH exhibited a trend toward decreased magnitude of SARS-CoV-2–specific antibodies, despite modestly increased overall response rates when compared with PWOH; (b) PLWH recovered from symptomatic outpatient COVID-19 had comparatively diminished immune responses; and (c) PLWH lacked a corresponding increase in SARS-CoV-2 antibodies with increased COVID-19 severity when asymptomatic versus symptomatic outpatient disease was compared.

Authors

Daniel J. Schuster, Shelly Karuna, Caroline Brackett, Martina Wesley, Shuying S. Li, Nathan Eisel, DeAnna Tenney, Sir’Tauria Hilliard, Nicole L. Yates, Jack R. Heptinstall, LaTonya D. Williams, Xiaoying Shen, Robert Rolfe, Robinson Cabello, Lu Zhang, Sheetal Sawant, Jiani Hu, April Kaur Randhawa, Ollivier Hyrien, John A. Hural, Lawrence Corey, Ian Frank, Georgia D. Tomaras, Kelly E. Seaton, HVTN 405/HPTN 1901 Study Team

×

Figure 2

SARS-CoV-2–specific IgG1, IgG3, and total IgG response rates and magnitudes at enrollment by HIV serostatus and peak COVID-19 symptom severity.

Options: View larger image (or click on image) Download as PowerPoint
SARS-CoV-2–specific IgG1, IgG3, and total IgG response rates and magnitu...
Response rates are shown at the top of each box plot. Colored dots/boxes designate peak symptom severity (blue, asymptomatic; red, symptomatic outpatient; teal, hospitalized). Gray triangles, nonresponders. Box plots represent the distribution for the positive responders only (number tested: PLWH IgG1 and IgG3 all antigens, n = 9 asymptomatic, n = 16 symptomatic outpatient, n = 18 hospitalized; PWOH IgG1 asymptomatic/symptomatic outpatient/hospitalized: N 64/130/130, NTD 40/82/103, RBD 63/131/130, 2P 64/133/129, 6P 40/79/102; PWOH IgG3 asymptomatic/symptomatic outpatient/hospitalized: N 64/131/131, NTD 65/131/131, RBD 64/131/131, 2P 65/132/131, 6P 63/130/131). Response magnitude is shown as net response in MFI in A and as AU in B. Prespecified IgG1 antigen-specific MFI positivity calls at 1:50 dilution were: RBD, 676; 2P spike, 1,967; 6P spike, 607; nucleoprotein, 1,666, NTD, 175. Instances of overlapping seropositive and seronegative responses at 1:1,000 dilution are below the positivity thresholds, and the positive responses at 1:50 are shown in Supplemental Figure 1. (A) IgG1 and IgG3. (B) Total IgG. PLWH recovered from symptomatic outpatient COVID-19 have significantly decreased response magnitudes for nucleoprotein-, NTD-, RBD-, and 6P spike–specific IgG1 (N: GMR 0.38, P = 0.004, q = 0.02; NTD: GMR 0.23, P < 0.001, q = 0.003; RBD: GMR 0.41, P = 0.005, q = 0.02; 6P spike: GMR 0.25, P < 0.001, q = 0.001) and 2P spike– and RBD-specific total IgG (2P: GMR 0.41, P =0.012, q = 0.054; RBD: GMR 0.43, P = 0.006, q = 0.053). Response rate differences are not present by HIV serostatus within symptom severity groups. Log-linear regression adjusting for peak COVID-19 symptom severity, diabetes, hypertension, COPD/emphysema/asthma, current and ever smoking, age, sex, BMI, race/ethnicity, region, and days since SARS-CoV-2 diagnosis was used. Asterisks and solid lines denote significant differences in response magnitude between PLWH and PWOH at P ≤ 0.05 and q ≤ 0.2 levels.